Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 3/2016

01-04-2016 | Original Article

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

Authors: Serena De Luca, Rosa Fonti, Luigi Camera, Barbara Salvatore, Antongiulio Faggiano, Andrea Ciarmiello, Sabrina Segreto, Annamaria Colao, Marco Salvatore, Silvana Del Vecchio

Published in: Annals of Nuclear Medicine | Issue 3/2016

Login to get access

Abstract

Objective

The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and indium-111 Octreotide single photon emission tomography (111In-Octreotide SPECT) in the evaluation of metastatic medullary thyroid carcinoma (MMTC).

Methods

Twenty-five MMTC patients were retrospectively evaluated. All patients had undergone whole-body 18F-FDG-PET/CT including 20 who had also undergone 111In-Octreotide SPECT within a maximum interval of 6 weeks. Diagnostic contrast-enhanced computed tomography (CT) alone or as part of 18F-FDG-PET/CT examination was performed in all patients.

Results

Contrast-enhanced CT detected a total of 131 lesions including 79 enlarged lymph nodes and 14 bone lesions. 18F-FDG-PET/CT visualized a total of 92 true positive lesions (SUVmax range 1.1–10.0, mean 4.0 ± 1.7) including 66 lymph nodes, 7 of which were not enlarged on CT, and 8 bone metastases. In the 20 patients studied with both techniques, a total of 64 and 46 true positive lesions were detected by 18F-FDG-PET/CT and 111In-Octreotide SPECT, respectively. In particular, 18F-FDG uptake was found in 43 lymph nodes and in 7 bone metastases whereas 111In-Octreotide uptake was detected in 27 lymph nodes and in 10 bone metastases.

Conclusions

In MMTC patients, 18F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas 111In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.
Literature
1.
Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4:22–32.CrossRefPubMed
2.
3.
Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012;8:466–75.CrossRefPubMed
4.
Giraudet AL, Al Ghulzan A, Auperin A, Leboulleux S, Chehboun A, Troalen F, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol. 2008;158:239–46.CrossRef
5.
Schlumberger M, Bastholt L, Dralle H, Jarzab B, Pacini F, Smit JW, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J. 2012;1:5–14.CrossRefPubMedPubMedCentral
6.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.CrossRefPubMed
7.
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.CrossRefPubMed
8.
Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. Am J Roentgenol. 2013;201:W867–76.CrossRef
9.
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.CrossRefPubMed
10.
Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 18F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136–42.CrossRefPubMed
11.
Skoura E, Datseris IE, Rondogianni P, Tsagarakis S, Tzanela M, Skilakaki M, et al. Correlation between calcitonin levels and [(18)F]FDG-PET/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer. ISRN Endocrinol. 2012;2012:375231.CrossRefPubMedPubMedCentral
12.
Gomez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vazquez-Albertino RJ, Navarro-Gonzalez E, Ruiz-Franco-Baux JV, et al. Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test. Rev Esp Med Nucl Imagen Mol. 2012;31:261–6.PubMed
13.
Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Impact of (18)F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Nucl Med Commun. 2011;32:1162–8.CrossRefPubMed
14.
Palaniswamy SS, Subramanyam P. Diagnostic utility of PET/CT in thyroid malignancies: an update. Ann Nucl Med. 2013;27:681–93.CrossRefPubMed
15.
Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767–72.CrossRefPubMedPubMedCentral
16.
Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46.CrossRefPubMedPubMedCentral
17.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323–30.CrossRefPubMedPubMedCentral
18.
19.
Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med. 2009;50(Suppl 1):97S–105S.CrossRefPubMed
20.
Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, et al. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med. 2011;52:231–40.CrossRefPubMed
21.
Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci. 2013;34:676–88.CrossRefPubMed
22.
Mato E, Matias-Guiu X, Chico A, Webb SM, Cabezas R, Berna L, et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:2417–20.PubMed
23.
Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf). 2001;54:641–9.CrossRef
24.
Christian JA, Cook GJ, Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. Br J Cancer. 2003;89:258–61.CrossRefPubMedPubMedCentral
25.
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.PubMed
26.
Gao Z, Biersack HJ, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol. 2004;130:649–56.CrossRefPubMed
27.
Lodish M, Dagalakis U, Chen CC, Sinaii N, Whitcomb P, Aikin A, et al. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab. 2012;97:E207–12.CrossRefPubMedPubMedCentral
28.
Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47.CrossRefPubMed
29.
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, et al. Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors. Clin Nucl Med. 2013;38:354–8.CrossRefPubMed
30.
Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829–35.CrossRefPubMed
31.
Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68 Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–80.CrossRefPubMed
32.
Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, et al. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr Radiopharm. 2013;6:96–105.CrossRefPubMed
33.
Chua S, Gnanasegaran G, Cook GJ. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:416–30.CrossRefPubMed
34.
Brabander T, Kwekkeboom DJ, Feelders RA, Brouwers AH, Teunissen JJ. Nuclear medicine imaging of neuroendocrine tumors. Front Horm Res. 2015;44:73–87.CrossRefPubMed
35.
van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nat Rev Endocrinol. 2014;10:102–14.CrossRefPubMed
36.
van Vliet EI, Hermans JJ, de Ridder MA, Teunissen JJ, Kam BL, de Krijger RR, et al. Tumor response assessment to treatment with [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors: differential response of bone versus soft-tissue lesions. J Nucl Med. 2012;53:1359–66.CrossRefPubMed
37.
Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, et al. Comparison of (68)Ga-DOTATATE PET–CT, (18)F-FDG PET–CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun. 2015;36:242–50.CrossRefPubMed
Metadata
Title
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma
Authors
Serena De Luca
Rosa Fonti
Luigi Camera
Barbara Salvatore
Antongiulio Faggiano
Andrea Ciarmiello
Sabrina Segreto
Annamaria Colao
Marco Salvatore
Silvana Del Vecchio
Publication date
01-04-2016
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 3/2016
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-1056-5

Other articles of this Issue 3/2016

Annals of Nuclear Medicine 3/2016 Go to the issue

Original Article

18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes

Original Article

Comparison of integrated whole-body PET/MR and PET/CT: Is PET/MR alternative to PET/CT in routine clinical oncology?

Review Article

Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis

Original Article

Development of a simple non-invasive microsphere quantification method for cerebral blood flow using I-123-IMP

Case Report

FDG PET/CT allowing detection and follow-up of tumor cell transplantation

Short Communication

A descriptive analysis of remnant activity during 90Y resin microspheres radioembolization of hepatic tumors: technical factors and dosimetric implications